Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Cash & Equivalents (2022 - 2024)

Adial Pharmaceuticals' Cash & Equivalents history spans 3 years, with the latest figure at $5.2 million for Q3 2024.

  • For Q3 2024, Cash & Equivalents changed N/A year-over-year to $5.2 million; the TTM value through Sep 2024 reached $5.2 million, changed N/A, while the annual FY2023 figure was $2.8 million, 29.35% down from the prior year.
  • Cash & Equivalents for Q3 2024 was $5.2 million at Adial Pharmaceuticals, up from $3.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $12.7 million in Q1 2022 and bottomed at $1.2 million in Q2 2023.
  • The 3-year median for Cash & Equivalents is $4.5 million (2022), against an average of $5.1 million.
  • The largest annual shift saw Cash & Equivalents tumbled 86.7% in 2023 before it soared 169.91% in 2024.
  • A 3-year view of Cash & Equivalents shows it stood at $4.0 million in 2022, then dropped by 29.35% to $2.8 million in 2023, then soared by 84.09% to $5.2 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Cash & Equivalents are $5.2 million (Q3 2024), $3.3 million (Q2 2024), and $5.0 million (Q1 2024).